shutterstock_1776573179_rafapress
rafapress / Shutterstock.com
2 September 2021GenericsAlex Baldwin

Endo International can’t stop Vasostrict generic

The US District Court for the District of Delaware has ruled that one of Endo International’s pharma units cannot stop a generic of its blood pressure drug Vasostrict (vasopressin injection) from being made.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Americas
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

More on this story

Americas
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Americas
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.

More on this story

Americas
22 July 2019   Ireland-headquartered Endo Pharmaceuticals agreed to pay $2.3 million to 18 states late last week, settling allegations that the drugmaker paid a competitor to keep a generic version of pain relief drug Lidoderm off the market.
Americas
24 January 2017   Endo Pharmaceuticals yesterday settled charges brought by the Federal Trade Commission by abandoning anti-competitive pay-for-delay agreements.